Company news
Silexion Therapeutics Corp (NASDAQ:SLXN) news
Every Silexion Therapeutics Corp press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
September 9, 2026
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
August 11, 2026
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourask...
July 29, 2026
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
July 29, 2026
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreati...
June 23, 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
May 26, 2026
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
May 15, 2026
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
May 14, 2026
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of P...
May 13, 2026
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Drive...
April 28, 2026
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advance...
March 24, 2026
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 17, 2026
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
March 5, 2026
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
January 21, 2026
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones ...
January 6, 2026
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Ca...
December 16, 2025
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
December 2, 2025
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
November 26, 2025
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Cli...
November 25, 2025
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhib...
September 30, 2025
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
September 25, 2025
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
September 11, 2025
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic S...
September 11, 2025
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
September 4, 2025
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
September 2, 2025
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
July 31, 2025
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against N...
July 31, 2025
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
July 16, 2025
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell...
July 9, 2025
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
May 29, 2025
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
May 21, 2025
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinic...
April 23, 2025
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
March 28, 2025
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCan...
March 21, 2025
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer...
March 5, 2025
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of ...
February 25, 2025
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
January 29, 2025
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
January 28, 2025
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
January 15, 2025
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancr...
January 15, 2025
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
January 13, 2025
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
December 17, 2024
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
December 10, 2024
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
November 22, 2024